^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ELVN-002

    i
    Other names: ELVN-002, ELVN 002, ELVN002
    Associations

    News

    Trials
    Company:
    Enliven Therapeutics
    Drug class:
    HER2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    A Study of ELVN-002 in Healthy Adult Volunteers: Part C (ACTRN12623000652673)
    P1, N=24, Withdrawn, Enliven Therapeutics, Inc. | Recruiting --> Withdrawn
    Trial withdrawal
    |
    itraconazole • ELVN-002
    2ms
    A Study of ELVN-002 in Healthy Adult Volunteers: Part A (ACTRN12623000440628)
    P1, N=48, Completed, Enliven Therapeutics, Inc. | Terminated --> Completed
    Trial completion
    |
    ELVN-002
    2ms
    A Study of ELVN-002 in Healthy Adult Volunteers: Part B (ACTRN12623000431628)
    P1, N=6, Terminated, Enliven Therapeutics, Inc. | Withdrawn --> Terminated
    Trial termination
    |
    ELVN-002
    5ms
    ELVN-002-003: ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer (clinicaltrials.gov)
    P1, N=275, Active, not recruiting, Enliven Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Herceptin (trastuzumab) • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • Halaven (eribulin mesylate) • leucovorin calcium • ELVN-002
    5ms
    ELVN-002-001: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=198, Active, not recruiting, Enliven Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 positive • BRAF V600E • HER-2 amplification • BRAF V600 • ALK mutation
    |
    Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • ELVN-002
    over1year
    ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer (clinicaltrials.gov)
    P1, N=255, Recruiting, Enliven Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Herceptin (trastuzumab) • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • Halaven (eribulin mesylate) • leucovorin calcium • ELVN-002
    over1year
    ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer (clinicaltrials.gov)
    P1, N=255, Not yet recruiting, Enliven Therapeutics
    New P1 trial • Metastases
    |
    Herceptin (trastuzumab) • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • Halaven (eribulin mesylate) • leucovorin calcium • ELVN-002
    almost2years
    ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=178, Recruiting, Enliven Therapeutics | Phase classification: P1a/1b --> P1
    Phase classification
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 positive • BRAF V600E • HER-2 amplification • BRAF V600 • ALK mutation
    |
    Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • ELVN-002
    2years
    A Study of ELVN-002 in Healthy Adult Volunteers: Part B (ACTRN12623000431628)
    P1, N=6, Not yet recruiting, Enliven Therapeutics, Inc.
    New P1 trial
    |
    ELVN-002
    2years
    A Study of ELVN-002 in Healthy Adult Volunteers: Part A (ACTRN12623000440628)
    P1, N=48, Not yet recruiting, Enliven Therapeutics, Inc.
    New P1 trial
    |
    ELVN-002
    over2years
    A Study of ELVN-002 in Healthy Adult Volunteers: Part C (ACTRN12623000652673)
    P1, N=24, Recruiting, Enliven Therapeutics, Inc. | Initiation date: May 2000 --> May 2023
    Trial initiation date
    |
    itraconazole • ELVN-002
    over2years
    A Study of ELVN-002 in Healthy Adult Volunteers: Part C (ACTRN12623000652673)
    P1, N=24, Recruiting, Enliven Therapeutics, Inc.
    New P1 trial
    |
    itraconazole • ELVN-002